Dosing to rash? - The role of erlotinib metabolic ratio from patient serum in the search of predictive biomarkers for EGFR inhibitor-mediated skin rash
详细信息 查看全文
- 作者：Michael Steffensa ; i ; michael.steffens@bfarm-research.de" class="auth_mail" title="E-mail the corresponding author ; Tanusree Paulb ; Vivien Hicherta ; i ; Catharina Scholla ; i ; Dirk von Malleka ; i ; Christoph Stelzerc ; Fritz Sö ; rgelc ; d ; Bä ; rbel Reiserb ; Christian Schumanne ; f ; Stefan Rü ; digere ; Stefan Boeckg ; Volker Heinemanng ; Volker Kä ; cheleh ; Thomas Seufferleinh ; Julia Stingla ; i
- 关键词：EGFR inhibitor-induced skin rash ; Erlotinib metabolic ratio ; Erlotinib/O-desmethyl-erlotinib ratio ; Predictive biomarker
- 刊名：European Journal of Cancer
- 出版年：2016
- 出版时间：March 2016
- 年：2016
- 卷：55
- 期：Complete
- 页码：131-139
- 全文大小：1101 K
文摘
- em" id="list_ulist0010">
- el">•
Severity of skin rash was associated with treatment outcome in terms of progression free survival (PFS) and overall survival (OS) in cancer patients treated with tyrosine kinase inhibitors.
- el">•
Drug-metabolising activity assessed by the erlotinib/O-desmethyl-erlotinib metabolic ratio was observed to be correlated with the severity of skin rash in that way that high metabolic activity lowers the occurrence of skin rash.
- el">•
The erlotinib/O-desmethyl-erlotinib metabolic ratio was also highly associated with PFS and OS in cancer patients.
- el">•
The individual metabolic activity of erlotinib determined in serum may be helpful for therapeutic monitoring in erlotinib treatment and decisions on individual dosing to rash in rash-negative cancer patients.